Christophe Ravoet

2.3k total citations
38 papers, 1.5k citations indexed

About

Christophe Ravoet is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Christophe Ravoet has authored 38 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 15 papers in Genetics and 13 papers in Oncology. Recurrent topics in Christophe Ravoet's work include Acute Myeloid Leukemia Research (14 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Christophe Ravoet is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Christophe Ravoet collaborates with scholars based in Belgium, France and United States. Christophe Ravoet's co-authors include Augustin Ferrant, André Bosly, Michael Lübbert, Márcia André, G. Verhoef, P. Wijermans, Gregor Verhoef, Regina Kunzmann, Pierre W. Wijermans and Marc André and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Christophe Ravoet

38 papers receiving 1.4k citations

Peers

Christophe Ravoet

HEMAT

ONCOL

GENET

IMMUN

Pascale Lepelley France

JM Cayuela France

Manuel Afable United States

Ana Rasillo Spain

Blythe Thomson United States

B Barlogie United States

Vittorio Montefusco Italy

Thomas Cluzeau France

Erin P. Demakos United States

Blanca Sánchez‐González Spain

Pascale Lepelley France

Christophe Ravoet

742 ×0.8

HEMAT

376 ×0.5

366 ×1.1

ONCOL

299 ×1.0

GENET

153 ×0.6

IMMUN

Citations per year, relative to Christophe Ravoet Christophe Ravoet (= 1×) peers Pascale Lepelley

Countries citing papers authored by Christophe Ravoet

Since Specialization

Citations

This map shows the geographic impact of Christophe Ravoet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Ravoet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Ravoet more than expected).

Fields of papers citing papers by Christophe Ravoet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Ravoet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Ravoet. The network helps show where Christophe Ravoet may publish in the future.

Co-authorship network of co-authors of Christophe Ravoet

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Ravoet. A scholar is included among the top collaborators of Christophe Ravoet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Ravoet. Christophe Ravoet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meers, Stef, Dimitri Breems, Michel Delforge, et al.. (2013). MANAGEMENT OF MYELODYSPLASTIC SYNDROMES IN ADULTS: GUIDELINES FROM THE BELGIAN HAEMATOLOGICAL SOCIETY*1 The responsibility of the content of these guidelines lies with the Belgian Haematological Society. The editorial board of the Acta Clinica Belgica is not responsible for eventual weaknesses or lack of evidence of the published document. Acta Clinica Belgica. 68(4). 253–262. 2 indexed citations

Kelaïdi, Charikleia, Sophie Park, Rosa Sapena, et al.. (2013). Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 27(6). 1283–1290. 47 indexed citations

Natarajan‐Amé, Shanti, Sophie Park, Lionel Adès, et al.. (2012). Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I / II Study by the GFM. British Journal of Haematology. 158(2). 232–237. 12 indexed citations

Delforge, Michel, A. Michiels, Alain Kentos, et al.. (2012). Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.. PubMed. 66(5). 371–5. 4 indexed citations

Delforge, Michel, Dominik Selleslag, Philippe Mineur, et al.. (2011). Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Annals of Hematology. 90(6). 655–666. 11 indexed citations

Park, Sophie, Charikleia Kelaïdi, Rosa Sapena, et al.. (2010). Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. Leukemia Research. 34(11). 1430–1436. 46 indexed citations

Adès, Lionel, Simone Boehrer, Thomas Prébet, et al.. (2008). Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 113(17). 3947–3952. 107 indexed citations

Meers, Stef, Ahmad Kasran, Louis Boon, et al.. (2007). Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells. Leukemia. 21(12). 2411–2419. 15 indexed citations

Ravoet, Christophe, et al.. (2004). Contribution of Flow Cytometry to the Diagnosis of Malignant and Non Malignant Conditions in Lymph Node Biopsies. Leukemia & lymphoma. 45(8). 1587–1593. 18 indexed citations

10.

Ribrag, Vincent, Florence Suzan, Christophe Ravoet, et al.. (2003). Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia. 17(2). 319–322. 5 indexed citations

11.

Ravoet, Christophe, Philippe Mineur, L Debusscher, et al.. (2002). Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML).. Blood. 100(11). 7 indexed citations

12.

Lübbert, Michael, Augustin Ferrant, P. Wijermans, et al.. (2000). Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor.. Blood. 96(11). 3 indexed citations

13.

Dewé, Walthère, et al.. (2000). A Four-Parameter Index of Marrow Dysplasia Has Predictive Value for Survival in Myelodysplastic Syndromes. Leukemia & lymphoma. 36(5-6). 485–496. 13 indexed citations

14.

Wijermans, P., Augustin Ferrant, Michael Luebbert, et al.. (1999). DNA demethylating therapy in MDS: The experience with 5-AZA-2 '-deoxycytidine (decitabine).. Blood. 94(10). 4 indexed citations

15.

Feremans, Walter, Fabian Moine, Christophe Ravoet, et al.. (1996). Simplification of the blood stem cell transplantation (BSCT) procedure: large volume apheresis and uncontrolled rate cryopreservation at –80°C. European Journal Of Haematology. 56(5). 278–282. 8 indexed citations

16.

Bosly, André, Augustin Ferrant, Anne Sonet, et al.. (1995). 2-Chlorodeoxyadenosine in refractory non-Hodgkin's lymphoma: A phase II study on 50 patients.. Blood. 86(10). 212–212. 4 indexed citations

17.

Feremans, Walter, Fabian Moine, Christophe Ravoet, et al.. (1994). Optimal blood stem cell mobilization using 10 μg/kg granulocyte colony‐stimulating factor (G‐CSF) alone for high‐dose melphalan intensification in multiple myeloma: An intrapatient controlled study. American Journal of Hematology. 47(2). 135–138. 7 indexed citations

18.

Tomiak, Eva, Martine Piccart, Joseph Kerger, et al.. (1994). Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.. Journal of Clinical Oncology. 12(7). 1458–1467. 125 indexed citations

19.

Ravoet, Christophe, Harry Bleiberg, & B. Gérard. (1993). Non-surgical treatment of hepatocarcinoma. Journal of Surgical Oncology. 53(S3). 104–111. 22 indexed citations

20.

Ravoet, Christophe, Martine Piccart, Dominique Bron, et al.. (1992). A phase I clinical trial of recombinant human interleukine-6 (rhIL-6) in solid tumors. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 232. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact